OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Shen on the Tolerability and Efficacy of ARX517 in mCRPC

November 7th 2023

John Shen, MD, discusses unique features associated with the use of the prostate-specific membrane antigen–directed antibody-drug conjugate ARX517 in patients with metastatic castration-resistant prostate cancer and highlights early efficacy and safety findings with this agent.

Dr Somaiah on the Peak Trial in GIST

November 7th 2023

Neeta Somaiah, MD, discusses enrollment criteria for the phase 3 Peak trial in patients with gastrointestinal stromal tumor and the advantages of this trial’s design.

Kelsen on DEI Initiatives at Columbia University in Patients With Cancer

November 6th 2023

Moshe Kelsen, MBA, discusses ongoing initiatives that aim to improve diversity, equity, and inclusion for patients with cancer receiving treatment at Columbia University.

Dr Henderson on Incorporating Immunotherapy Agents into Practice in Bladder Cancer

November 6th 2023

R. Jonathan Henderson, MD, discusses incorporating immunotherapy agents into practice in patients with bladder cancer.

Dr Lowentritt on the Exploration of Active Surveillance in Prostate Cancer

November 6th 2023

Benjamin H. Lowentritt, MD, FACS, discusses the exploration of active surveillance in patients with prostate cancer.

Dr Morris on Active Surveillance in Low- and Intermediate-Risk Patients With Prostate Cancer

November 3rd 2023

David Morris, MD, FACS, discusses the best practices for active surveillance in low- and intermediate-risk patients with prostate cancer, highlighting factors to look for in patients undergoing active surveillance that may point to the need for further treatment.

Dr Crawford on the Evolving Role of Active Surveillance in Prostate Cancer

November 3rd 2023

E. David Crawford, MD, discusses the evolving role of active surveillance in patients with prostate cancer.

Dr Komrokji on Ongoing Investigations With Luspatercept in MDS

November 3rd 2023

Rami Komrokji, MD, discusses the benefit of agents such as luspatercept-aamt in patients with very low– to intermediate-risk myelodysplastic syndromes who have not received prior treatment with erythropoiesis-stimulating agents.

Dr Baretti on the Utility of FGFR Inhibitors in FGFR2+ Intrahepatic Cholangiocarcinoma

November 3rd 2023

Marina Baretti, MD, discusses the evolving utility of FGFR inhibitors in the treatment of patients with unresectable, advanced, or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 gene fusions or other rearrangements.

Dr Jayram on the Role of Immunotherapy in Bladder Cancer

November 3rd 2023

Gautam Jayram, MD, discusses the current indications for immunotherapy agents in the bladder cancer treatment paradigm, as well as immune-related adverse effects to be aware of when treating patients who are receiving these therapies.

Dr Spratt on Sequencing Radiation Therapy and Hormone Therapy in Prostate Cancer

November 2nd 2023

Daniel Spratt, MD, discusses research findings that have delineated the optimal sequencing of radiation therapy and hormone therapy for patients with prostate cancer.

Dr Nieva on the Rationale for Investigating At-Home Atezolizumab Administration in NSCLC

November 1st 2023

Jorge Nieva, MD, discusses the rationale and design of an ongoing phase 2 trial investigating a telemedicine approach to delivering subcutaneous atezolizumab for patients with non–small cell lung cancer.

Dr Shields on Updates in Upfront Systemic Therapy in ES-SCLC

November 1st 2023

Misty D. Shields, MD, PhD, discusses systemic therapy updates for patients with extensive-stage small cell lung cancer.

Dr Creelan on the Investigation of A2B530 in Advanced or Metastatic NSCLC

November 1st 2023

Benjamin Creelan, MD, discusses the investigation of A2B530 in patients with advanced or metastatic non–small cell lung cancer.

Dr Kaczmar on the Future Utility of Cemiplimab With Fianlimab in Advanced Melanoma

November 1st 2023

John Michael Kaczmar, MD, discusses future implications for the use of fianlimab in combination with cemiplimab for the treatment of patients with advanced melanoma.

Dr Meric-Bernstam on the Efficacy of T-DXd in HER2-Expressing Solid Tumors

November 1st 2023

Funda Meric-Bernstam, MD, discusses results from the phase 2 DESTINY-PanTumor02 trial of fam-trastuzumab deruxtecan-nxki in HER2-expressing solid tumors.

Dr Weber on Survival Outcomes With mRNA-4157 Plus Pembrolizumab in High-Risk Melanoma

November 1st 2023

Jeffrey S. Weber, MD, PhD, discusses findings from the phase 2b mRNA-4157-P201/KEYNOTE-942 trial of mRNA-4157 in combination with pembrolizumab in resected high-risk melanoma.

Dr Passaro on the Significance of the TROPION-Lung05 Trial of Dato-DXd in NSCLC

November 1st 2023

Antonio Passaro, MD, PhD, medical oncologist, Division of Thoracic Oncology, European Institute of Oncology, discusses the significance of data from the phase 2 TROPION-Lung05 trial of datopotamab deruxtecan in patients with non–small cell lung cancer.

Dr Liu on the Significance of T-DXd For Patients With HER2-Mutant NSCLC and Brain Metastases

October 31st 2023

Stephen V. Liu, MD, discusses the significance of using fam-trastuzumab deruxtecan-nxki in patients with HER2-mutant non–small cell lung cancer and brain metastases according to pooled findings from exploratory analyses of the phase 2 DESTINY-Lung01 and DESTINY-Lung02 trials.

Dr Murthy on the Use of CAR T-Cell Therapy in Elderly or Frail Patients With B-Cell Lymphomas

October 30th 2023

Hemant S. Murthy, MD, discusses the evolving use of CAR T-cell therapy for elderly or frail patients with relapsed/refractory B-cell lymphomas.